199 related articles for article (PubMed ID: 22865093)
1. B-cell receptor pathobiology and targeting in NHL.
Macias-Perez IM; Flinn IW
Curr Oncol Rep; 2012 Oct; 14(5):411-8. PubMed ID: 22865093
[TBL] [Abstract][Full Text] [Related]
2. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways.
Kenkre VP; Kahl BS
Curr Hematol Malig Rep; 2012 Sep; 7(3):216-20. PubMed ID: 22688757
[TBL] [Abstract][Full Text] [Related]
3. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
4. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
Sawas A; Diefenbach C; O'Connor OA
Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
[TBL] [Abstract][Full Text] [Related]
6. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
Rodgers TD; Reagan PM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323
[TBL] [Abstract][Full Text] [Related]
7. B-cell receptor pathway modulators in NHL.
Blum KA
Hematology Am Soc Hematol Educ Program; 2015; 2015():82-91. PubMed ID: 26637705
[TBL] [Abstract][Full Text] [Related]
8. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Alinari L; Quinion C; Blum KA
Clin Pharmacol Ther; 2015 May; 97(5):469-77. PubMed ID: 25670208
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
[TBL] [Abstract][Full Text] [Related]
11. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
Choe H; Ruan J
Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
[TBL] [Abstract][Full Text] [Related]
12. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibitors: lessons learned from bench-to-bedside (first) studies.
Ysebaert L; Michallet AS
Curr Opin Oncol; 2014 Sep; 26(5):463-8. PubMed ID: 25033375
[TBL] [Abstract][Full Text] [Related]
14. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
Jahangiri S; Friedberg J; Barr P
Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
[TBL] [Abstract][Full Text] [Related]
15. Novel agents in mantle cell lymphoma.
Noel MS; Friedberg JW; Barr PM
Best Pract Res Clin Haematol; 2012 Jun; 25(2):191-200. PubMed ID: 22687455
[TBL] [Abstract][Full Text] [Related]
16. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
Winer ES; Ingham RR; Castillo JJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):355-61. PubMed ID: 22300471
[TBL] [Abstract][Full Text] [Related]
17. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
Mato A; Jauhari S; Schuster SJ
Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
[TBL] [Abstract][Full Text] [Related]
18. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
19. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
20. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
